Existing tests for mental states rely largely on self-reports and are difficult to reproduce. Subjective measurements lead to longer clinical trials, higher costs and missed opportunities. MoSeq AI® can provide objective scores for neuropsychiatric and neuromuscular indications.
MoSeq AI® can strengthen our understanding of interventions in the preclinical testing phase. By tracking the behavioral expressions of laboratory animals, we can help pharmaceutical companies advance the right compounds to the clinical testing phase.
MoSeq AI® can assist physicians with remote diagnostics and care. Our technology enables continuous, objective assessments that can inform better patient care.